Chemotherapy-Free Triplet 'Sets a New Benchmark' in Follicular Lymphoma

(MedPage Today) — ORLANDO — Adding the bispecific antibody epcoritamab (Epkinly) to a standard chemotherapy-free regimen for relapsed or refractory follicular lymphoma improved responses and reduced the risk of disease progression or death…